Summit Wealth Group LLC Co. Has $386,000 Stock Holdings in Amgen Inc. $AMGN

Summit Wealth Group LLC Co. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 76.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,179 shares of the medical research company’s stock after selling 3,778 shares during the quarter. Summit Wealth Group LLC Co.’s holdings in Amgen were worth $386,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares in the last quarter. Capital International Investors lifted its holdings in Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Capital World Investors lifted its holdings in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after buying an additional 1,935,876 shares in the last quarter. Capital Research Global Investors lifted its holdings in Amgen by 2.7% during the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock worth $1,335,168,000 after buying an additional 122,631 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Amgen by 6.6% during the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock worth $1,260,668,000 after buying an additional 277,031 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN stock opened at $336.45 on Thursday. The business’s fifty day moving average is $351.05 and its 200-day moving average is $342.80. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a market cap of $181.58 billion, a P/E ratio of 23.41, a price-to-earnings-growth ratio of 3.38 and a beta of 0.44. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the prior year, the company earned $4.90 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts forecast that Amgen Inc. will post 22.36 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. Amgen’s dividend payout ratio is currently 70.15%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

AMGN has been the topic of a number of analyst reports. Leerink Partners reissued a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Royal Bank Of Canada increased their price target on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. TD Cowen reissued a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Truist Financial increased their price target on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Finally, Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $356.35.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.